Fabtech Technologies Limited · NSE:FABTECH
Fabtech Technologies — CVOCA Investocraft 2026
15 slides from Fabtech Technologies's conference presentation, Feb 27, 2026

Slide 1: Exchange filing cover letter: Investor Presentation
Date: February 27, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Cod

Slide 2: India's Global Life Sciences Infrastructure Platform
India’s Global Life Sciences Infrastructure Platform Engineering Medicinal Sovereignty Across Continents

Slide 3: Medicinal Sovereignty driving a 15-year buildout
Medicinal Sovereignty is driving a 15-year Lifescience infrastructure buildout across GCC, Middle East & Africa and surrounding nations. Fabtech is positioned as: Design & Diversified Local Policy-aligned Build-led dosage form execution infrastructure portfolio presence partner

Slide 4: Execution Strength
Execution Strength Integrated capabilities: Process Engineering Air (HVAC, containment) End-to-end process design and engineering Cleanroom HVAC and containment systems. expertise. Water (WFI, PW, PS systems) In-house manufacturing leverage Water for Injection and Purified Water systems. Controlled

Slide 5: Our ecosystem
Our ecosystem Fabtech Jo FABTECH nowmiooeuc Fabtech Technolog’ s Limited Engineering | Iva Fabtech Fabtech

Slide 6: Total Addressable Market (TAM)
Total Addressable Market (TAM) GCC Market Maghreb Africa (UAE, KSA, Qatar, Oman, Kuwait, Bahrain) (Algeria, Morocco, Tunisia, Libya) (Egypt, Ethiopia, Kenya, Nigeria + emerging) Estimated Pharma Capex Estimated Pharma Capex Estimated Pharma Capex (2025–2040): (2025–2040): (2025–2040): USD 40–50 Bill

Slide 7: Why This is a 15-Year Pipeline
Why This is a 15-Year Pipeline Countries evolve manufacturing capability in stages: Oral solids Oncology Packaging Ointments Injectables Liquids Biosimilars APIs Biotech Vaccines Each stage requires: Process Engineering Cleanroom & HVAC Systems Packaging lines Water Systems Validation Regulatory Int

Slide 8: Our Strategic Presence
Our Strategic Presence Geographic Footprint: UAE operating base Saudi footprint References in Africa European entity acquisition (technical credibility & conversion lever) Conversion Rate Growth: Post-Acquisition Target 20% Current conversion 10% Doubling hit rate = exponential growth on same lead b

Slide 9: Value Chain: Role of a Turnkey Engineering Solution Provider
VALUE CHAIN: ROLE OF A TURNKEY ENGINEERING SOLUTION PROVIDER Design Engineering Procurement Construction Management + Project Controls Advisory Consulting Design & Vendor Selection New Plant/ Plant Procurement of Technology Tie-up/ Conception Upgradation Equipment Systems Transfer Project Audit, Tra

Slide 10: Proven Benchmark Projects
Proven Benchmark Projects First Egyptian Flu Vaccine Project Largest IV Solution Facility – Saudi First Oncology Project – Saudi First Biosimilars Facility – Saudi UAE's Only USFDA Approved Facility These Create: Regulatory Credibility Entry Barriers Reference Moat Repeat Pipeline

Slide 11: Order Book & Pipeline
Order Book & Pipeline Orders in hand Current confirmed orders ready for execution in the coming periods. ≈926Cr As on 31st Jan 26 Conversion Target Improving conversion rate post-European acquisition for structural visibility. 10% to 20%

Slide 12: Why Fabtech
Why Fabtech Early mover in medicinal First-mover biotech & vaccine Policy-aligned infra independence corridors references positioning Technical depth across dosage Local presence in capital formats decision geographies

Slide 13: We are building medicinal sovereignty infrastructure across continents
We are not building factories. We are building medicinal sovereignty infrastructure across continents 15-year structural opportunity. Scalable execution model Reference-led moat.

Slide 14

Slide 15: Thank You
THANK YOU 62+countries, Experience of Expertise across Design, In-house manufacturing by Start-to-Finish partner for pharma, completing2000+projects in Engineering, Installation, & group companies ensure pharma, biotech &healthcare different countries Certification execution speed
Source: NSE filing, Feb 27, 2026
More decks from Fabtech Technologies Limited
Q2 & H1 FY27 Earnings Presentation35 slides · Oct 30, 2026
Q1 FY2026-27 Earnings Presentation20 slides · Jul 28, 2026
Investor Presentation (June 2026)22 slides · Jun 23, 2026
FY2026 Earnings Presentation9 slides · Apr 28, 2026
9M FY26 Earnings Presentation11 slides · Feb 9, 2026
Q2 FY26 Earnings Presentation14 slides · Nov 6, 2025